

Cover Story
NCI Director's Report
By Matthew Bin Han Ong
After a year of lean appropriations, NCI is looking at what threatens to be a budgetary cataclysm—a potential 10-11% cut to the Labor-HHS spending bill in fiscal year 2025.
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- Caught in the crossfire: The critical threats facing cancer centers, research, and patient care
- Columbia’s cancer center becomes collateral damage in Trump’s war on antisemitism
- Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills - FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- Trump’s tariffs will likely affect cancer drugs and devices—and may deepen drug shortages
- The University of Rochester Wilmot Cancer Institute earns NCI Cancer Center designation